Loading
II
Immunovaccine Inc. Stock: price and insider trades · Canada
Immunovaccine Inc.: what insiders have been doing
This page follows insider dealings at Immunovaccine Inc. as filed with SEDI. The past year has been quiet: not a single insider filing for Immunovaccine Inc. The previous disclosure was published on 29 April 2018.
The full history, which starts in 2016, counts 98 purchases against 1 sale.
Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Insider Decl.
143
Thresholds
n/a
Buy Volume
€1M
98 ops. · all time
Sell Volume
€203,145
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 29 April 2018
Declarations143 total
55,000 shares@ CA$1.8012.8% of flowCommon SharesTSXSEDI:3176448
Canonical exit: 25 Jul 2018 (T+90)
45,000 shares@ CA$1.8210.5% of flowCommon SharesTSXSEDI:3176447
Canonical exit: 24 Jul 2018 (T+90)
10,000 shares@ CA$1.002.5% of flowCommon SharesTSXSEDI:3161344
500 shares@ CA$1.980.5% of flowCommon SharesTSXSEDI:3158041
Canonical exit: 20 Jun 2018 (T+90)
9,500 shares@ CA$1.999.6% of flowCommon SharesTSXSEDI:3158043
Canonical exit: 20 Jun 2018 (T+90)
16,000 shares@ CA$1.88419.0% of flowCommon SharesTSXSEDI:3132324
Canonical exit: 14 May 2018 (T+90)
20,800 shares@ CA$1.8915.9% of flowCommon SharesTSXSEDI:3132255
Canonical exit: 13 May 2018 (T+90)
10,000 shares@ CA$2.052.7% of flowCommon SharesTSXSEDI:3129504
Canonical exit: 3 May 2018 (T+90)
10,000 shares@ CA$2.002.6% of flowCommon SharesTSXSEDI:3129505
Canonical exit: 6 May 2018 (T+90)
33,600 shares@ CA$2.099.2% of flowCommon SharesTSXSEDI:3123612
Canonical exit: 24 Apr 2018 (T+90)
5,300 shares@ CA$2.173.5% of flowCommon SharesTSXSEDI:3118002
Canonical exit: 12 Apr 2018 (T+90)
10,000 shares@ CA$2.179.0% of flowCommon SharesTSXSEDI:3117317
Canonical exit: 12 Apr 2018 (T+90)
5,000 shares@ CA$2.256.1% of flowCommon SharesTSXSEDI:3116160
Canonical exit: 9 Apr 2018 (T+90)
5,000 shares@ CA$2.226.0% of flowCommon SharesTSXSEDI:3116161
Canonical exit: 10 Apr 2018 (T+90)
30,900 shares@ CA$0.2810.0% of flowCommon SharesTSXSEDI:3116168
20,000 shares@ CA$2.246.0% of flowCommon SharesTSXSEDI:3108090
Canonical exit: 27 Mar 2018 (T+90)
9,100 shares@ CA$0.931.0% of flowCommon SharesTSXSEDI:3056206
Canonical exit: 4 Dec 2017 (T+90)
5,000 shares@ CA$0.940.6% of flowCommon SharesTSXSEDI:3056209
Canonical exit: 4 Dec 2017 (T+90)
6,490 shares@ CA$0.940.7% of flowCommon SharesTSXSEDI:3052432
Canonical exit: 28 Nov 2017 (T+90)
900 shares@ CA$0.920.1% of flowCommon SharesTSXSEDI:3051880
Canonical exit: 27 Nov 2017 (T+90)
100,000 shares@ CA$1.2214.4% of flowCommon SharesTSXSEDI:3040865
Canonical exit: 22 Oct 2017 (T+90)
26,825 shares@ CA$1.2211.0% of flowCommon SharesTSXSEDI:3040796
Canonical exit: 26 Oct 2017 (T+90)
25,000 shares@ CA$1.2210.2% of flowCommon SharesTSXSEDI:3038690
Canonical exit: 18 Oct 2017 (T+90)
10,000 shares@ CA$1.3012.8% of flowCommon SharesTSXSEDI:3024653
30,000 shares@ CA$1.3038.4% of flowCommon SharesTSXSEDI:3024655
25 of 143 declarations
About Immunovaccine Inc.
Immunovaccine Inc. is a biopharmaceutical company focused on developing therapeutic vaccines for the treatment of cancer and other diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.
